19 September 2008
Mayo risk score for primary biliary cirrhosis: A useful tool for the prediction of course after liver transplantation?
Dietmar A. Jacob, Marcus Bahra, Sven C. Schmidt, Guido Schumacher, Andreas Weimann, Peter Neuhaus, Ulf P. NeumannAnn Transplant 2008; 13(3): 35-42 :: ID: 868537
Abstract
Background: Survival after orthotopic liver transplantation (OLT) for primary biliary cirrhosis (PBC) is excellent. In order to define the optimal time point for OLT, the Mayo risk score (MRS) was developed and a score of 7.8 was identified for transplantation. However, in reality most recipients are in a bad condition with a MRS above 7.8. So far it is still unknown if a higher score is associated with more complications after OLT perioperatively and in a long-term follow-up. Therefore, this study was designed to investigate the association of the MRS score with postoperative survival and complications.
Material/Methods: Between 1989 and 2006, 115 patients were transplanted for histologically proven PBC at the Charité Campus Virchow Clinic. In 98 of these patients, MRS data was available and retrospectively analyzed. Median age of 87 women and 11 men was 54 years (25 to 66 years).
Results: The median follow-up after liver transplantation was 109 months (0.5–205 months). Actuarial patient survival after 5, 10 and 15 years was 90%, 88%, and 83%. Calculated survival by MRS without transplantation after 1, 5 and 7 years was 20%, 2% and 1% for these patients. Twelve patients (12%) died and histological recurrence of PBC was detected in 14 patients (14%). Seven patients underwent retransplantation (7%) and 58 patients developed an acute rejection episode (59%). Mean MRS was in all patients 9.54±1.35 and did not differ between patients with lethal course, retransplantations, PBC recurrence, rejection episodes and duration of hospital stay. Classification of all patients into a low (<8.5), middle (8.5–10) and high MRS score (>10) did not show a significant difference in long-term survival. Univariate analysis for identifying the level of MRS as risk for death, PBC-recurrence, retransplantation, acute rejection episodes and hospital stay only showed a significant increased risk for acute rejection episodes (1 episode = 0.04; 2 episodes = 0.01) for patients with a MRS above 8.5.
Conclusions: The Mayo risk score is an approved mathematical model predicting survival in non-transplanted patients suffering from PBC. However, the score did not predict the course of our liver transplanted patients in a long-term follow-up. We could not demonstrate a reduced patient survival at a median MRS of 9.4 and about 10.0. Therefore, it is, from our point of view, questionable if the optimal time point for OLT is still 7.8.
Keywords: Liver Transplantation, mayo risk score, Survival
In Press
Original article
Common Versus External Iliac Arterial Anastomosis in Kidney Transplantation: A Bicentric Retrospective Anal...Ann Transplant In Press; DOI: 10.12659/AOT.953269
Original article
Protective Effects of Quercetin and Sucrose on Cold Preservation Injury in Porcine Kidneys Donated After Ca...Ann Transplant In Press; DOI: 10.12659/AOT.952503
Original article
Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952888
Original article
Determinants of Lack of Consent for Deceased Organ Donation Among Nurses and Physicians: A Cross-Sectional ...Ann Transplant In Press; DOI: 10.12659/AOT.953598
Most Viewed Current Articles
24 Aug 2021 : Review article 21,160
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,335
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,325
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,249
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






